Indian Journal of Modern Research and Reviews

This Journal is a member of the *'Committee on Publication Ethics'*

Online ISSN:2584-184X

Research Article

From Field to Formulation: Agriculture, Mass Production, Processing and Markets of Ashwagandha and Panax Ginseng in India

Bipul Kumar Jha [1*], Dr. Ankita Pareekh [2]

[1] Research Scholar, Department of Commerce and Management, Banasthali Vidyapith, Tonk, Rajasthan, India

[2] Assistant Professor, FMS WISDOM, Banasthali Vidyapith, Tonk, Rajasthan, India

Corresponding Author: * Bipul Kumar Jha

DOI: https://doi.org/10.5281/zenodo.22825730

Abstract

Ashwagandha (Withania somnifera (L.) Dunal) and Asian ginseng (Panax ginseng C.A. Mey.) are frequently placed in the same commercial 'adaptogen' category, yet their Indian production systems are fundamentally different. This review maps cultivation, scale-up, post-harvest handling, extraction, quality assurance and market geography for both crops, with particular attention to states and production regions. Ashwagandha is a short-duration, drought-tolerant crop embedded in India's medicinal-plant economy. Its strongest production-trade corridor lies in western Madhya Pradesh, especially Neemuch-Mandsaur and neighbouring areas, with complementary production in Rajasthan and reported cultivation across Gujarat, Maharashtra, Uttar Pradesh, Haryana, Punjab and parts of southern India. Neemuch functions as a pivotal aggregation and price-discovery centre, while processing and consumption extend through pharmaceutical, Ayurvedic, nutraceutical and digital retail clusters across India. Panax ginseng, by contrast, requires cool conditions, artificial or forest shade, stratified seed, disease management and a four-to-six-year root cycle. Indian evidence is concentrated in the western Himalayan region; a five-year trial in Lahaul and Spiti demonstrated agronomic adaptation and measurable ginsenosides, but this does not yet establish a national commercial supply base. Consequently, Indian ginseng products are better understood as an import-dependent or imported-input value chain with a possible future Himalayan cultivation segment. The paper proposes differentiated scale-up models: contract-linked dryland clusters, graded root procurement and traceable extraction for ashwagandha; and protected pilot estates, nursery infrastructure, long-horizon finance and identity-preserved processing for Panax ginseng. Across both species, botanical authentication, plant-part disclosure, marker-based standardization, contaminant control and transparent market data are the critical conditions for converting demand into durable farmer and manufacturing value.

Manuscript Information

- **ISSN No:** 2584-184X
- **Received:** 09-06-2026
- **Accepted:** 26-07-2026
- **Published:** 30-07-2026
- **MRR:**4(7); 2026: 282-289

- **Plagiarism Checked:** Yes
- **Peer Review Process:** Yes

How to Cite this Article

Jha B K, Pareekh A. From Field to Formulation: Agriculture, Mass Production, Processing and Markets of Ashwagandha and Panax Ginseng in India. Indian J Mod Res Rev. 2026;4(7):282-289.

Access this Article Online

www.mrrjournal.in

KEYWORDS: Withania somnifera; Panax ginseng; medicinal plants; cultivation geography; extraction; value chain; herbal markets; India

1. INTRODUCTION

India's botanical-health economy connects farming, forest and nursery systems with raw-drug mandis, extract manufacturers, Ayurvedic pharmacies, nutraceutical companies, wholesalers and online retail. Ashwagandha and ginseng illustrate two sharply different routes through that economy. Ashwagandha is botanically Withania somnifera, a member of Solanaceae, and the name 'Indian ginseng' is a functional or marketing analogy rather than a taxonomic identity. True Asian or Korean ginseng is Panax ginseng, a slow-growing Araliaceae perennial whose principal marker compounds are ginsenosides. Conflating the crops can lead to incorrect assumptions about suitable states, crop duration, processing equipment, regulatory identity and commercial risk.

The distinction is especially important for agricultural and investment decisions. Ashwagandha can be integrated into semi-arid rotations and harvested within one season. Its root value depends on morphology, cleanliness, plant part, genotypeq111e, maturity and constituent profile. Panax ginseng ties up shaded land and working capital for several years and needs specialized planting material and disease control. The final ginseng root may be sold fresh, dried as white ginseng, or steamed and dried as red ginseng, creating process-linked product identities that have no direct equivalent in conventional ashwagandha trade.

This review asks four questions: (1) where can each crop be cultivated in India and where is it already concentrated; (2) what technical and organizational systems are needed for mass production; (3) how do primary processing, extraction and standardization shape value; and (4) which Indian markets perform the main functions of aggregation, manufacturing, distribution and consumption? The objective is not to claim a complete agricultural census, because medicinal-plant statistics are fragmented and published estimates differ by year and method. Instead, the paper triangulates authoritative agronomic guidance, peer-reviewed research and institutional market information to identify robust patterns, evidence gaps and commercially realistic pathways.

2. REVIEW APPROACH AND EVIDENCE BOUNDARIES

A structured narrative-review approach was used. Sources were selected for their relevance to Indian agronomy, regional suitability, post-harvest technology, extraction, market organization and regulation. Priority was given to publications of the National Medicinal Plants Board (NMPB), state and agricultural institutions, CSIR laboratories, food and drug regulators, peer-reviewed journal articles and recognized pharmacopoeial or scientific reviews. The attached Bengaluru retail-positioning study informed the broad manuscript architecture—context, methods, results-oriented synthesis, implications and limitations—but the present text and analysis were independently developed for the agriculture-to-market question.

Three evidence cautions apply. First, estimates of national ashwagandha area, production and demand are not always contemporaneous or methodologically comparable. Older extension pages remain useful for agronomic ranges, but they should not be presented as current census values. Second, market arrival data measure traded lots, not total output or consumption. Third, the successful cultivation of P. ginseng at an Indian experimental location demonstrates feasibility under those conditions; it does not prove that large volumes, stable farmer economics or a domestic seed-and-processing ecosystem already exist. Claims in this paper are therefore classified as established, reported, or prospective where appropriate.

3. BOTANICAL AND PRODUCTION-SYSTEM CONTRAST

Table 1. Why "Indian ginseng" and Panax ginseng require separate value-chain analysis

Dimension	Ashwagandha	Panax ginseng	Strategic consequence
Botanical identity	Withania somnifera; Solanaceae	Panax ginseng; Araliaceae	Separate germplasm, tests and labels are required.
Crop habit	Short-duration shrub grown as an annual crop in commercial fields	Shade-requiring perennial root crop, commonly harvested after several years	Working-capital and land-lock periods differ radically.
Indian production status	Established cultivation and raw-root trade	Experimental/emerging Himalayan cultivation; finished market substantially reliant on foreign-origin material	Scale-up models cannot be copied from one crop to the other.
Primary valued material	Usually root; leaves may enter distinct extract streams but must not be silently substituted	Root/rhizome; age and white/red processing identity materially affect value	Plant part and process history must accompany each batch.
Main marker family	Withanolides/withanosides, alongside alkaloids and other constituents	Ginsenosides	Analytical methods and specifications are not interchangeable.
Typical production risk	Price volatility, uneven grading, variable chemistry, contamination and weak traceability	Seed dormancy, long juvenile period, root disease, shade cost, climatic mismatch and import dependence	Different insurance, contracting and extension arrangements are needed.

4. ASHWAGANDHA AGRICULTURE IN INDIA

4.1 Agro-ecology and crop establishment

Ashwagandha is suited to relatively dry subtropical conditions and is valued as a hardy, drought-tolerant medicinal crop. Light to medium, well-drained soils are preferred; excessive fertility or water can encourage vegetative growth without necessarily improving commercial root quality. The crop is commonly established with the monsoon through direct sowing or nursery-raised transplants, depending on local practice, seed availability and weed pressure. Uniform stands are important because root form and maturity influence grading. The species' tolerance of lower-input environments creates opportunities in rain-fed districts, but 'hardy' should not be interpreted as management-free: seed quality, drainage, plant density, weed control and timely harvesting directly affect saleable root.

Extension guidance places average commercial dry-root yields in the range of roughly 300-500 kg per hectare, with higher outcomes possible under favourable genotype and management; such ranges are contextual rather than guaranteed. A crop generally matures when berries ripen and aerial parts senesce, often about five to six months after sowing. Delayed or wet harvesting increases the risk of staining, microbial damage and root breakage. Root length, diameter, colour, fibre content and freedom from crown pieces and foreign matter are commercially visible traits, while withanolide profile and contaminants require laboratory testing (TNAU Agritech Portal, n.d.; Mirjalili et al., 2009).

4.2 State and regional production geography

Table 2. Indian ashwagandha production and value-chain regions

State/region	Representative zones	Current role	Why the region matters
Madhya Pradesh	Neemuch, Mandsaur and the Malwa-western MP belt; reported links to Manasa and Jawad	Core cultivation, aggregation, auction/trade and primary processing	Dryland fit, established mandi institutions, trader density and access to grading/extraction.
Rajasthan	South-eastern districts adjoining the MP corridor; cultivation also reported in drier central/northern belts	Major complementary production and inward supply to MP markets	Semi-arid ecology and geographic continuity with the Neemuch-Mandsaur trade system.
Gujarat	Dry and semi-arid districts; institutional medicinal-plant research and processing base	Cultivation and industrial linkage	Strong botanical-extract, pharmaceutical and port-oriented manufacturing ecosystem.
Maharashtra	Dry interior districts and western/central processing corridors	Diversified cultivation and formulation demand	Access to Mumbai-Pune manufacturers, traders and consumer markets.
Uttar Pradesh	Drier plains and medicinal-plant clusters; Lucknow research-manufacturing influence	Cultivation, research, Ayurveda and extraction	Proximity to CSIR-CIMAP and large north-Indian pharmaceutical demand.
Haryana and Punjab	Irrigated north-west plains, generally as a diversification crop	Smaller reported cultivation and important consuming/formulating region	Good logistics, contract-farming potential and north-Indian distribution.
Andhra Pradesh/Telangana and Karnataka	Selected dry tracts; southern herbal and nutraceutical manufacturing clusters	Emerging/secondary cultivation and major processing-consumption role	Hyderabad and Bengaluru provide laboratories, brands, contract manufacturers and digital demand.
Tamil Nadu	Dry zones with Siddha/Ayurvedic demand and agricultural extension capability	Secondary cultivation, traditional medicine and formulation	Links field supply to Chennai-Coimbatore processing and southern markets.

Western Madhya Pradesh is the most consistently documented centre. The Neemuch district administration describes Neemuch as a prominent herb-trading centre and identifies ashwagandha as a major auctioned root; the district also hosts dehydration and herbal-extraction activity. Extension sources similarly pair Neemuch with Mandsaur as nationally important procurement markets. This concentration gives the region advantages in buyer discovery, lot assembly and quality sorting, but it can also transmit local production shocks and bargaining imbalances through a geographically concentrated trade node (District Neemuch, 2026; TNAU Agritech Portal, n.d.).

4.3 A scalable farm-production model

Mass production should be understood as coordinated replication of quality-controlled farms, not simply expansion of planted area. A viable cluster model begins with authenticated seed of a defined variety or chemotype, farmer training and a buy-back specification stated before sowing. Procurement specifications should include permitted plant part, harvest window, maximum moisture, foreign matter, root-size grades, pesticide expectations, microbial limits and the analytical basis for withanolide claims. Digital lot codes can connect village, farmer, seed lot, field practices and harvest date to the processor's certificate of analysis.

Cluster planning: locate acreage within economical reach of a drying, grading and aggregation centre; avoid scattered procurement that makes traceability costly.

Seed and nursery control: verify botanical identity and germination; retain reference samples and seed-lot records.

Good agricultural and collection practices: record inputs, prevent waterlogging, manage weeds early and observe pre-harvest intervals.

Harvest synchronization: schedule labour, root lifting, washing and drying so wet roots are not held in heaps.
Quality-linked payment: pay separately for root grade, cleanliness, moisture and verified chemistry rather than using a single undifferentiated rate.
Market-risk sharing: combine a floor price or formula with transparent grade premiums; avoid promising returns based only on a temporary spot price.

5. PANAX GINSENG AGRICULTURE: INDIA'S EMERGING HIMALAYAN CASE

5.1 Climatic fit and regional prospects

Panax ginseng is adapted to cool temperate environments and naturally shaded forest-floor conditions. Commercial systems reproduce that environment with forest cultivation or artificial shade, well-drained beds, organic-matter management and careful disease prevention. Seeds exhibit complex dormancy and normally require stratification; planting-material quality therefore becomes a strategic bottleneck. The long crop cycle exposes growers to several monsoons, winters and disease seasons before revenue is realized.
The strongest direct Indian evidence comes from CSIR-Institute of Himalayan Bioresource Technology researchers in Lahaul and Spiti, Himachal Pradesh. Five-year plants produced mature roots and seeds, and laboratory analysis identified 14 ginsenosides with total measured ginsenosides of 31.81 ± 2.89 mg/g in the reported samples. The authors concluded that the tested western Himalayan soil and climate were suitable for P. ginseng. CSIR-IHBT cultivation guidance also identifies inner temperate forest areas of Chamba, Kullu and Kinnaur as potential forest-grown zones (Walia et al., 2023; CSIR-IHBT, n.d.).
These findings justify expanded multi-location evaluation in Himachal Pradesh and carefully screened cold regions of Uttarakhand, Jammu and Kashmir/Ladakh and parts of the north-eastern Himalaya. They do not justify blanket promotion across these states. Site selection must consider winter chilling, summer temperature, slope and drainage, shade, disease pressure, altitude-specific phenology, access and conservation safeguards. Native Himalayan Panax taxa must not be harvested or marketed as P. ginseng without authoritative identity testing and compliance with biodiversity and forest rules.

5.2 Constraints on commercial mass production

Table 3. Constraints and responses for Panax ginseng scale-up in India

Constraint	Commercial effect	Scale-up response
Four-to-six-year production horizon	Land and capital remain committed; farmer exit and contract default risks rise	Long-term purchase contracts, milestone finance, crop insurance research and intercropping only where agronomically safe.
Stratified seed and nursery scarcity	Irregular germination and expensive planting material limit expansion	Central disease-screened nurseries, seed orchards, provenance records and phased acreage.
Shade infrastructure	High upfront cost and vulnerability to snow/wind	Compare forest-grown and engineered-shade models; standardize locally repairable structures.
Root diseases and replant problems	Multi-year losses can erase project economics	Raised beds, drainage, sanitation, rotation, diagnostic support and avoidance of rapid replanting.
Identity and age verification	Misidentified or young roots undermine quality and pricing	DNA/barcode or validated botanical tests, age records, retained samples and chain-of-custody.
Imported-market competition	Domestic roots must compete with mature Korean/Chinese supply chains	Target verified Indian-origin niches first; disclose species, root age, process and ginsenoside profile.
Limited Indian price/yield series	Bankable returns cannot be inferred from a single trial	Replicated techno-economic pilots with annual survival, labour, yield, chemistry and price data.

6. POST-HARVEST HANDLING, REFINING AND INDUSTRIAL PROCESSING

6.1 Ashwagandha: root to standardized ingredient

Ashwagandha value can be retained or destroyed in the first hours after lifting. Soil and damaged tissue should be removed without prolonged soaking. Roots are cut to a buyer-agreed size and dried promptly under hygienic conditions until safe storage moisture is achieved. Lots should remain separated by farmer, field, plant part and harvest period. Grading converts an undifferentiated heap into market categories based on root form, thickness, colour, breakage and contamination. Dry root can then move to whole-root trade, coarse cut, powder, classical formulation or extraction.
Industrial extraction usually follows cleaning, milling, controlled solvent contact, solid-liquid separation, concentration and drying. Water or hydro-alcoholic systems are common choices, but the process must be designed around the intended constituent spectrum, residual-solvent limits and regulatory category. Vacuum concentration reduces thermal exposure; spray drying converts concentrated extract into a flowable powder, often with an appropriate carrier. The extract is blended to reduce batch variability and standardized to a declared marker specification. Chromatographic testing should distinguish a scientifically defensible withanolide method from an unqualified 'total withanolides' number, because methods, reference standards and plant parts can produce non-comparable results (Shinde et al., 2023; Avula et al., 2026).

6.2 Panax ginseng: white, red and extracted products

Fresh ginseng is highly perishable and must be cleaned with minimal root damage. Drying peeled or unpeeled roots produces forms generally traded as white ginseng. Controlled steaming followed by drying produces red ginseng and changes colour, storage stability and the ginsenoside profile through

heat-associated transformations. Process temperature, duration, root size and moisture endpoint must be validated rather than treated as culinary steps. Powdered-root and extract lines require milling, aqueous or hydro-alcoholic extraction, filtration, concentration and drying, followed by ginsenoside profiling and contaminant testing (Baeg & So, 2013; Fan et al., 2023).

For an Indian-origin ginseng programme, the process identity should begin at the plot. Root age, cultivation system, provenance, harvest date and fresh weight should accompany each lot. A processor should avoid blending experimental Indian roots with imported material if the finished product makes an Indian-origin claim. This identity-preserved approach supports research and premium differentiation, although it raises segregation and testing costs.

Table 4. Critical control points from root receipt to finished ingredient

Stage	Ashwagandha control point	Panax ginseng control point	Shared quality output
Raw-material receipt	Root/leaf segregation; root grade; moisture and foreign matter	Species, provenance, root age, fresh/dry or white/red status	Approved supplier and quarantined lot
Authentication	Macroscopy/microscopy plus validated identity method	Species-level botanical/molecular authentication where needed	Confirmed identity and retained reference sample
Primary processing	Wash, cut and dry without mould or excessive browning	Gentle washing; validated drying or steam-drying cycle	Stable, traceable intermediate
Extraction	Validated water/hydro-alcoholic process matched to marker target	Validated extraction preserving/measuring ginsenoside spectrum	Documented extract ratio and mass balance
Chemical testing	Withanolide/withanoside profile using a declared method	Ginsenoside profile, not merely unspecified "ginseng extract"	Specification-linked certificate of analysis
Safety testing	Microbial load, aflatoxins, pesticides, heavy metals, residual solvents	Same, with attention to multi-year soil and treatment history	Compliant release decision
Formulation and label	Plant part, extract ratio, marker basis, serving and category	Species, root age/process where claimed, marker basis and serving	Truthful, comparable consumer information

7. MAJOR INDIAN MARKETS AND VALUE-CHAIN NODES

7.1 Raw-drug aggregation and price formation

For ashwagandha, Neemuch and Mandsaur form the most visible origin-market complex. Produce from surrounding Madhya Pradesh and adjoining states can be assembled, graded and moved to processors. Other published price-series locations—Shivpuri, Dhamtari, Kolkata and Mumbai—show that the commodity is connected to spatially dispersed markets, although price transmission is incomplete. Chavan (2024) found long-run linkage only among selected market pairs and highlighted infrastructure and information weaknesses. NMPB also identifies major herbal mandis and publishes reference-price initiatives, but a continuous national, grade-specific series remains difficult to construct (NMPB, n.d.-a, n.d.-b).

A 'major market' should therefore be defined by function. Origin mandis assemble farm output; industrial clusters convert roots to extracts and formulations; metro wholesale markets redistribute products; and urban/digital markets generate final demand. Bengaluru is significant as a southern technology, pharmacy, wellness and e-commerce market, but it is not the principal ashwagandha farm-gate price-discovery centre. For Panax ginseng, India's market is predominantly a finished-product and imported-ingredient market; no Indian mandi has yet been shown to perform for domestically grown P. ginseng what Neemuch does for ashwagandha.

Table 5. Functional geography of major Indian markets

Market/node	Primary function	Ashwagandha position	Panax ginseng position
Neemuch-Mandsaur, Madhya Pradesh	Origin aggregation, grading, auction/trading, primary processing	Nationally important core	No comparable established role
Indore-Ujjain-Pithampur corridor	Logistics, extraction and pharmaceutical linkage near origin	Value addition and regional distribution	Potential formulation/import distribution
Ahmedabad-Vadodara-Ankleshwar, Gujarat	Botanical extracts, pharma manufacturing and export logistics	Major processing opportunity	Imported-extract formulation and testing
Mumbai-Pune, Maharashtra	Wholesale trade, brand headquarters, ports, nutraceutical and consumer demand	National redistribution and high-value processing	Major import, premium retail and formulation market
Delhi-NCR and north-Indian wholesale markets	National distribution, e-commerce and Ayurveda/nutraceutical demand	Large consumption and redistribution node	Large premium nutraceutical market
Lucknow/UP clusters	Medicinal-plant research, Ayurveda and manufacturing	Research, cultivation support and processing	Analytical/formulation role more than farm production
Hyderabad, Telangana	Pharma, contract manufacturing, laboratories and digital retail	Extract/formulation and southern distribution	Formulation and premium retail
Bengaluru, Karnataka	Wellness brands, modern pharmacy, e-commerce, R&D and affluent consumption	High-value finished market and product-development node	Important niche retail market; supply largely external
Chennai/Coimbatore,	Siddha/Ayurveda manufacturing and southern	Traditional and modern	Niche finished-product demand

Tamil Nadu	distribution	formulation demand	
Himachal temperate districts	Prospective farm origin and research	Not a primary ashwagandha advantage zone	Best-documented Indian cultivation opportunity; still emerging

7.2 Demand segments

Ashwagandha demand is diversified across classical Ayurvedic preparations, single-herb powders, tablets and capsules, standardized extracts, sports nutrition, stress-and-sleep products, functional beverages, practitioner channels and exports. Panax ginseng is narrower and more premium: imported or import-derived capsules, energy and vitality combinations, traditional East Asian products, cosmetics, beverages and standardized extracts. The category overlap occurs at the consumer-benefit level, not at the farm or processing level.

Retail architecture can obscure underlying ingredient economics. A low-priced small ginseng pack may still carry a high price per unit, while a large ashwagandha pack may have a higher total MRP but a lower per-dose price. The attached Bengaluru audit found precisely this contrast in its sampled stock-keeping units: ginseng occupied smaller packs and a higher adjusted unit-price position, whereas ashwagandha appeared in larger, routine-use packs. That retail evidence is consistent with—though it does not prove—the upstream contrast between an import-sensitive premium ingredient and a domestically established botanical.

8. ECONOMICS AND ORGANIZATION OF MASS PRODUCTION

8.1 Ashwagandha: cluster expansion with demand discipline

Ashwagandha has the agronomic characteristics required for rapid acreage response, but rapid response can create boom-bust cycles. When farmers enter after observing a high spot price, harvests may arrive together and depress rates. Contract production can reduce this risk only if buyers specify volume and quality credibly. Farmer producer organizations can aggregate small lots, own cleaning and drying infrastructure, negotiate laboratory services and sell graded material rather than untested mixed roots. Processors benefit from fewer, traceable supplier interfaces and more consistent mass balance.

A processing hub should be sized from contracted dry-root supply, not aspirational acreage. Capacity calculations must account for fresh-to-dry conversion, sorting rejects, extraction yield, seasonal operating days, solvent recovery, drying capacity and batch-release time. Because chemical content varies, a tonne of root is not a tonne of standardized commercial value. Procurement based only on physical weight can reward dilution and penalize careful growers; a two-part price—base grade plus laboratory-linked premium—better aligns incentives.

8.2 Panax ginseng: a staged industrialization pathway

A national ginseng programme should progress through gates. Stage 1 is replicated agronomic validation across a small number of screened Himalayan sites. Stage 2 establishes stratified-seed and nursery capacity, disease diagnostics and multi-year cost records. Stage 3 creates pilot white/red ginseng and extract lines with identity-preserved batches. Only after survival, yield, ginsenoside profile, market acceptance and farmer returns are reproduced should Stage 4 expand contract acreage. Import substitution should be treated as an outcome to be measured, not an assumption used to justify planting.

Long-horizon finance is essential. A four-to-six-year root crop cannot be evaluated with the same seasonal credit logic as ashwagandha. Contracts require provisions for crop failure, quality bands, root age, early termination, land transfer and force majeure. A nursery or anchor processor may need to carry much of the biological and market risk during the demonstration phase. Public research support is justified for germplasm, pathology, analytical methods and location trials; routine commercial risk should progressively move to enterprises once repeatable economics exist.

9. QUALITY, REGULATION AND SUSTAINABILITY

9.1 Quality assurance and authenticity

Quality begins with a testable specification rather than a botanical name on an invoice. An international review of commercial ginseng reported substantial authenticity problems across the studied products, including species substitution and use of non-recommended plant parts. Ashwagandha products also show variability in plant part and measured steroidal-lactone composition. These findings should not be converted into an India-specific adulteration percentage, but they establish the need for supplier qualification, botanical authentication and orthogonal chemical testing (Ichim & de Boer, 2021; Avula et al., 2026).

Finished products in India may follow different legal routes depending on composition, intended use and claims, including Ayurveda/ASU drug or food/nutraceutical frameworks. The Ayurveda Aahara Regulations, health-supplement and nutraceutical requirements, labelling provisions and advertising-and-claims rules cannot be reduced to a single herb list. Manufacturers should determine classification for the complete product and maintain evidence for claims. Applicable food products must not be presented as treatments merely because the ingredient has traditional use (FSSAI, 2022; FSSAI, n.d.).

9.2 Environmental and social safeguards

Ashwagandha's dryland suitability can diversify farm income, but sustainability claims require field evidence. Expansion should not displace food crops without local assessment, and irrigation should not be added simply to maximize biomass where it lowers root quality or water productivity. Residues and spent plant material should be managed safely. Solvent

recovery and energy-efficient concentration are important environmental controls in extract plants.

Ginseng's risks are different. Forest-grown models must protect native vegetation, avoid illegal collection and prevent genetic or commercial confusion with native Panax species. Artificial shade has material and end-of-life impacts, while multi-year disease management can create pesticide pressure. Traceability should therefore include land status, cultivation system and treatment history. Benefit-sharing and biodiversity obligations require legal review when Indian biological resources or traditional knowledge are involved.

10. RESEARCH AND POLICY AGENDA

Table 6. Priority research programme for India

Priority	Ashwagandha research need	Panax ginseng research need	Proposed output
Production statistics	Annual district-level area, yield and grade	Separate experimental acreage from commercial harvest	Comparable national dashboard with definitions
Genotype × environment	Multi-location yield, root grade and withanolide stability	Multi-altitude survival, maturity and ginsenoside stability	Region-specific cultivar recommendations
Farm economics	Panel data across price cycles and contract types	Full five-year cash flow, mortality and shade depreciation	Risk-adjusted enterprise budgets
Post-harvest	Drying kinetics, microbial risk and grade retention	Validated white/red processing for Indian-grown roots	GACP/GMP-aligned process protocols
Market information	Grade-specific mandi arrivals and prices	Import volume/value by species and processed form	Transparent price and trade series
Quality methods	Harmonized, declared withanolide method and plant-part test	Species authentication and ginsenoside fingerprint	Inter-laboratory validated methods
Farmer organization	FPO-led grading, testing and contracting models	Nursery-anchor-farmer long-term contract design	Replicable institutional models
Consumer value	Link specification and dose to price and repeat purchase	Test willingness to pay for verified Indian origin	Evidence-based positioning rather than generic claims

Policy should focus on market infrastructure and verifiable quality rather than acreage targets alone. For ashwagandha, timely market arrivals, grade-specific prices, accredited regional laboratories, shared dryers and model contracts would address immediate bottlenecks. For Panax ginseng, competitive grants for replicated long-duration trials and a verified planting-material system are more defensible than large planting subsidies before economics are known. In both cases, public statistics should keep species and product form separate; aggregating raw roots, extracts and multi-ingredient finished products produces misleading trade signals.

11. MANAGERIAL IMPLICATIONS

Growers and producer organizations should select the crop according to their risk horizon. Ashwagandha can fit a seasonal diversification strategy where a credible buyer and drying route exist. Panax ginseng is suitable only for screened cool sites and partners able to carry multi-year agronomic and market risk. Traders should publish grade definitions and avoid mixing plant parts. Extract manufacturers should disclose the extraction ratio, solvent system at an appropriate technical level, marker method and mass-balance controls. Finished-product companies should connect the consumer claim to species, plant part, daily dose and evidence rather than relying on the undifferentiated word 'adaptogen.'

For Bengaluru-based firms, the strategic opportunity differs by herb. Ashwagandha offers domestic backward integration through MP-Rajasthan origin partnerships, regional testing and contract extraction. Panax ginseng offers product development, authentication, imported-input governance and, over a longer horizon, research partnerships with Himalayan institutions. Bengaluru is thus more naturally a formulation, quality, technology and demand node than a primary production region for either crop, particularly P. ginseng.

12. LIMITATIONS

This review does not present a new farm survey or a harmonized national production census. Several institutional agronomy pages contain undated or legacy estimates, and state-level production series are incomplete. The geographic table identifies well-supported core and reported secondary regions; it should not be read as a ranking by current tonnage. Market importance is assessed by function and published evidence, not by audited revenue. Ginseng conclusions are constrained by the scarcity of Indian multi-location, long-term commercial data. Finally, processing conditions are described at the unit-operation level because proprietary extract specifications vary and journal evidence does not support a single universally optimal process.

13. CONCLUSION

Ashwagandha and Panax ginseng occupy the same wellness conversation but not the same Indian agricultural economy. Ashwagandha already possesses the foundations of mass production: short crop duration, dryland adaptation, multiple producing states, an established western Madhya Pradesh trading core and a broad domestic manufacturing base. Its next productivity gain will come less from indiscriminate acreage expansion than from authenticated seed, cluster drying, objective grading, chemistry-linked procurement, transparent prices and stable buyer contracts.

Panax ginseng is an opportunity of a different order. Western Himalayan research demonstrates biological feasibility at a

specific site and supports further cultivation trials, but the long crop cycle, seed biology, shade requirement, pathology risk and absent domestic trading ecosystem make immediate mass-scale claims premature. A staged, evidence-gated strategy—research plots, nurseries, protected pilot cultivation, identity-preserved processing and verified premium markets—is the prudent route. For both species, India's durable competitive advantage will depend on converting botanical origin into documented quality and equitable value distribution from farmer to finished product.

REFERENCES

1. Avula B, Katragunta K, Tatapudi KK, Wang YH, Chittiboyina AG, Khan IA. A comparison of British and US Pharmacopoeia standards for quality of ashwagandha dietary supplements in commerce. Phytother Res. 2026;40(8):4833-4844. doi:10.1002/ptr.70148.
2. Baeg IH, So SH. The world ginseng market and the ginseng (Korea). J Ginseng Res. 2013;37(1):1-7. doi:10.5142/jgr.2013.37.1.
3. Chavan S. Price dynamics of ashwagandha (Withania somnifera) in India. Tradit Med Rev. 2024;4(2):53-64.
4. Chen W, Balan P, Popovich DG. Analysis of ginsenoside content (Panax ginseng) from different regions. Molecules. 2019;24(19):3491. doi:10.3390/molecules24193491.
5. CSIR-Institute of Himalayan Bioresource Technology. Ginseng (Panax ginseng): cultivation and agrotechnology. Palampur: CSIR-Institute of Himalayan Bioresource Technology.
6. District Neemuch. Economy. Government of Madhya Pradesh; 2026. Available from: https://neemuch.nic.in/en/economy/
7. Fan JW, Xu XT, Cheng H, Sang Z, Shi YH. Standardization of Panax ginseng: current status of global trade, demands, and development. Am J Chin Med. 2023;51(4):909-927. doi:10.1142/S0192415X23500428.
8. Food Safety and Standards Authority of India. Food Safety and Standards (Ayurveda Aahara) Regulations, 2022. New Delhi: Government of India; 2022.
9. Food Safety and Standards Authority of India. Food Safety and Standards Regulations. New Delhi: Government of India. Available from: https://www.fssai.gov.in/food-law/regulations
10. Goraya GS, Ved DK. Medicinal plants in India: an assessment of their demand and supply. New Delhi: National Medicinal Plants Board, Indian Council of Forestry Research and Education; 2017.
11. Ichim MC, de Boer HJ. A review of authenticity and authentication of commercial ginseng herbal medicines and food supplements. Front Pharmacol. 2021; 11:612071. doi:10.3389/fphar.2020.612071.
12. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009;14(7):2373-2393. doi:10.3390/molecules14072373.
13. Mikulska P, Malinowska M, Ignacyk M, Szustowski P, Nowak J, Pesta K, et al. Ashwagandha (Withania somnifera)—current research on the health-promoting activities: a narrative review. Pharmaceutics. 2023;15(4):1057. doi:10.3390/pharmaceutics15041057.
14. National Medicinal Plants Board. Marketing and trade. New Delhi: Ministry of AYUSH, Government of India. Available from: https://nmpb.nic.in/content/marketing-trade
15. National Medicinal Plants Board. Market price of medicinal plants. New Delhi: Ministry of AYUSH, Government of India. Available from: https://nmpb.nic.in/content/market-price-medicinal-plants
16. Paul S, Chakraborty S, Anand U, Dey S, Nandy S, Ghorai M, et al. Withania somnifera (L.) Dunal (Ashwagandha): a comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomed Pharmacother. 2021;143:112175. doi:10.1016/j.biopha.2021.112175.
17. Shinde S, Balasubramaniam AK, Mulay V, Saste G, Girme A, Hingorani L. Recent advancements in extraction techniques of Ashwagandha (Withania somnifera) with insights on phytochemicals, structural significance, pharmacology, and current trends in food applications. ACS Omega. 2023;8(44):40982-41003. doi:10.1021/acsomega.3c03491.
18. Singh M, Kaur N, Paul AT. Physicochemical standardization, HPTLC profiling, and biological evaluation of Ashwagandhadyarishta: a comparative study of three commercial brands. Anc Sci Life. 2014;33(3):165-171. doi:10.4103/0257-7941.144621.
19. Tamil Nadu Agricultural University Agritech Portal. Ashwagandha. Coimbatore: Tamil Nadu Agricultural University; [date unknown] [cited 2026 Sep 18]. Available from: https://agritech.tnau.ac.in/farm_enterprises/Farm%20enterprises_%20Ashwagantha.html
20. Walia S, Kumar P, Kumar D, Kumar R. A preliminary study on suitability of growing ginseng (Panax ginseng Meyer) in the western Himalayan region. Plant Soil Environ. 2023;69(2):71-80. doi:10.17221/288/2022-PSE.

About the Corresponding Author

Bipul Kumar Jha is a Research Scholar in the Department of Commerce and Management at Banasthali Vidyapith, Tonk, Rajasthan, India. His academic interests focus on healthcare, commerce, and management, with particular emphasis on contemporary business practices, healthcare management, and organizational issues. His research contributes to emerging perspectives and knowledge across these interdisciplinary fields.